This inventor holds 2 USPTO granted patents, plus 1 CIPO patent. Top assignees: Jiangsu Hengrui Medicine Company Ltd., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai Senhui Medicine Co., Ltd.. Active years: 2025-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025-2026
Title: Yinggang Tang: Innovator in Neurokinin-1 Antagonist Development
Introduction
Yinggang Tang is a notable inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of neurokinin-1 antagonists. His work focuses on creating compounds that can effectively treat diseases related to the neurokinin-1 receptor.
Latest Patents
Yinggang Tang holds a patent for a neurokinin-1 antagonist, which is represented by a specific formula. This compound, or its pharmaceutically acceptable salt, is designed to avoid hemolytic effects of drugs and reduce the side effects associated with drug administration. The innovation in this patent highlights the potential for improved therapeutic options in treating various medical conditions.
Career Highlights
Throughout his career, Yinggang Tang has worked with prominent companies in the pharmaceutical industry. He has been associated with Shanghai Shengdi Pharmaceutical Co., Ltd and Shanghai Senhui Medicine Co., Ltd. His experience in these organizations has contributed to his expertise in drug development and innovation.
Collaborations
Yinggang Tang has collaborated with notable professionals in his field, including Jian Huang and Lingjian Zhu. These partnerships have likely enhanced his research and development efforts, leading to advancements in pharmaceutical innovations.
Conclusion
Yinggang Tang's contributions to the field of neurokinin-1 antagonists demonstrate his commitment to improving medical treatments. His innovative approach and collaboration with industry professionals position him as a key figure in pharmaceutical advancements.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile